10x Genomics $TXG Shares Acquired by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP significantly increased its stake in 10x Genomics by 579.7%, acquiring a total of 97,151 shares worth approximately $848,000.
• Several institutional investors have also boosted their positions in 10x Genomics, with notable increases from firms like Signaturefd LLC and PNC Financial Services Group Inc..
• 10x Genomics reported better-than-expected earnings of $0.28 per share and a revenue of $172.91 million for the last quarter, surpassing analysts' estimates.

Voleon Capital Management LP lifted its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 579.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,151 shares of the company's stock after purchasing an additional 82,857 shares during the period. Voleon Capital Management LP owned about 0.08% of 10x Genomics worth $848,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of TXG. GAMMA Investing LLC boosted its holdings in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares during the last quarter. Xponance Inc. boosted its holdings in 10x Genomics by 17.4% in the 1st quarter. Xponance Inc. now owns 12,010 shares of the company's stock valued at $105,000 after purchasing an additional 1,778 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in 10x Genomics in the 4th quarter valued at about $32,000. AlphaQuest LLC raised its position in 10x Genomics by 8.3% in the first quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock valued at $257,000 after purchasing an additional 2,258 shares during the period. Finally, Signaturefd LLC raised its position in 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the period. Hedge funds and other institutional investors own 84.68% of the company's stock.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of research analyst reports. Stephens restated an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research report on Thursday, May 15th. Piper Sandler initiated coverage on 10x Genomics in a research report on Thursday. They issued a "neutral" rating and a $15.00 target price on the stock. Barclays restated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Bank of America lifted their target price on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Thursday, June 26th. Finally, Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and a consensus price target of $13.65.

Insider Buying and Selling

In other news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares of the company's stock, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,149 shares of company stock valued at $539,865. Insiders own 9.39% of the company's stock.

10x Genomics Stock Performance

NASDAQ:TXG traded down $0.42 during mid-day trading on Friday, hitting $12.64. 2,515,960 shares of the company's stock traded hands, compared to its average volume of 2,146,278. The firm's 50 day simple moving average is $13.21 and its 200 day simple moving average is $10.81. The company has a market cap of $1.57 billion, a PE ratio of -18.06 and a beta of 2.00. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics's revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, research analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.